Bispecific Nanoparticle Bioconjugates for Stable Cancer-Immune Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific antibodies suffer from low conformational and formulation stability, leading to a short serum half-life and rapid elimination from the body, limiting their effectiveness in cancer treatment.
Innovation Solution
Nanoparticle bioconjugates are developed with a dumbbell or flower-like configuration, comprising a first nanoparticle conjugated to a cancer cell-binding protein and a second nanoparticle conjugated to an immune cell-binding protein, utilizing metallic and magnetic nanoparticles to enhance stability and serum half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific antibodies are used for cancer treatment, then therapeutic effectiveness is improved through simultaneous binding to tumor cells and immune cells, but conformational and formulation stability deteriorates leading to short serum half-life
Solution Approach 1:
The patent combines two different nanoparticle materials (metallic and magnetic) into a composite bioconjugate structure. Each nanoparticle type contributes different properties: metallic nanoparticles provide structural stability and conjugation platforms, while magnetic nanoparticles enhance cellular uptake and provide additional functional capabilities. This composite approach resolves the stability issue while maintaining therapeutic effectiveness.
Solution Approach 2:
The bispecific antibody function is segmented into two separate nanoparticle components, each carrying one binding protein. This segmentation allows each nanoparticle to be optimized independently for stability and function, with the metallic nanoparticle focusing on structural integrity and the magnetic nanoparticle focusing on cellular interaction, thereby resolving the overall stability problem.
2Reliability
If bisspecific antibodies are used for cancer treatment, then therapeutic effectiveness is improved, but serum half-life deteriorates due to rapid elimination from the body
Solution Approach 1:
The patent changes the physical and chemical parameters of the antibody molecule by replacing it with nanoparticle-based bioconjugates. The nanoparticles have different size, surface area, and compositional parameters that optimize serum persistence. The metallic and magnetic nanoparticle combination creates a structure that resists renal filtration and proteolytic degradation, thereby extending serum half-life while maintaining therapeutic activity.
3Measurement precision
If conventional bispecific antibodies are used, then binding specificity to target moieties is achieved, but conformational stability deteriorates
Solution Approach 1:
The nanoparticle structure serves as an intermediary platform that stabilizes the binding proteins. The metallic and magnetic nanoparticles act as rigid scaffolds that maintain the conformational integrity of the conjugated binding proteins, preventing their degradation while preserving their specific binding capabilities to target moieties on cancer cells and immune cells.
Data Source
AI summary
The present invention relates to nanoparticle bioconjugates comprising binding proteins for binding to a cancer cell and an antigen of an immune cell, and uses and methods of treatment comprising administration thereof.